{"id":"rosiglitazone-4-mg-day","safety":{"commonSideEffects":[{"rate":"null","effect":"Fluid retention"},{"rate":"null","effect":"Weight gain"},{"rate":"null","effect":"Edema"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Activation of PPAR-γ by rosiglitazone results in the transcriptional regulation of genes involved in glucose and lipid metabolism. This leads to increased insulin sensitivity and glucose uptake in adipose tissue, as well as decreased glucose production in the liver.","oneSentence":"Rosiglitazone activates PPAR-γ, leading to increased insulin sensitivity and glucose uptake in adipose tissue.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:45.744Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04114136","phase":"PHASE2","title":"Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2020-09-14","conditions":"Melanoma, NSCLC, Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT00004180","phase":"PHASE2","title":"Rosiglitazone in Treating Patients With Liposarcoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"1999-10","conditions":"Sarcoma","enrollment":32},{"nctId":"NCT01019356","phase":"NA","title":"Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Jean-Patrice Baillargeon","startDate":"2006-08","conditions":"Polycystic Ovary Syndrome","enrollment":52},{"nctId":"NCT00265148","phase":"PHASE2","title":"Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05-18","conditions":"Alzheimer's Disease","enrollment":80},{"nctId":"NCT00616642","phase":"PHASE2","title":"Rosiglitazone in Treating Patients With Pituitary Tumors","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2006-10","conditions":"Brain and Central Nervous System Tumors","enrollment":1},{"nctId":"NCT04148183","phase":"PHASE2, PHASE3","title":"Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients.","status":"COMPLETED","sponsor":"J JESUS VENEGAS, MD","startDate":"2004-01-01","conditions":"Insulin Resistance","enrollment":30},{"nctId":"NCT00427154","phase":"PHASE3","title":"Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2007-01-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":227},{"nctId":"NCT00194896","phase":"NA","title":"Preferred Treatment of Type 1.5 Diabetes","status":"COMPLETED","sponsor":"University of Washington","startDate":"2000-02","conditions":"Type 2 Diabetes Mellitus","enrollment":64},{"nctId":"NCT00065065","phase":"PHASE2","title":"A Trial of Rosiglitazone for Ulcerative Colitis","status":"COMPLETED","sponsor":"James Lewis","startDate":"2002-09","conditions":"Ulcerative Colitis, Inflammatory Bowel Disease","enrollment":105},{"nctId":"NCT00964106","phase":"PHASE1","title":"Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-26","conditions":"Drug Interactions","enrollment":87},{"nctId":"NCT00640224","phase":"PHASE4","title":"Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study","status":"COMPLETED","sponsor":"Silva Arslanian","startDate":"2005-03","conditions":"Polycystic Ovary Syndrome","enrollment":65},{"nctId":"NCT00551564","phase":"PHASE1","title":"Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-31","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT00511823","phase":"PHASE1","title":"The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-23","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":16},{"nctId":"NCT00733785","phase":"PHASE1","title":"PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-08-13","conditions":"Alzheimer's Disease","enrollment":60},{"nctId":"NCT01332071","phase":"PHASE1","title":"Avandamet Bioequivalence Study Brazil - Fed Administration","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-24","conditions":"Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00879970","phase":"PHASE4","title":"Thiazolidinedione Intervention With Vitamin D Evaluation","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1332},{"nctId":"NCT00481663","phase":"PHASE2","title":"A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08-19","conditions":"Type II Diabetes Mellitus","enrollment":555},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":"Diabetes Mellitus, Type 2","enrollment":4447},{"nctId":"NCT00348712","phase":"PHASE3","title":"Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-10-30","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":301},{"nctId":"NCT00343980","phase":"PHASE3","title":"Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-10-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":363},{"nctId":"NCT00242619","phase":"NA","title":"Insulin Resistance in Patients With Mood Disorder","status":"COMPLETED","sponsor":"Stanford University","startDate":"2007-07","conditions":"Depression, Bipolar Disorder, Insulin Resistance","enrollment":12},{"nctId":"NCT00831129","phase":"PHASE2, PHASE3","title":"A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2006-09","conditions":"Pre-diabetes","enrollment":53},{"nctId":"NCT00186537","phase":"NA","title":"Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.","status":"COMPLETED","sponsor":"Stanford University","startDate":"2003-09","conditions":"Insulin Resistance, Hypertriglyceridemia","enrollment":47},{"nctId":"NCT00386100","phase":"PHASE4","title":"A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":688},{"nctId":"NCT00486187","phase":"NA","title":"Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study","status":"COMPLETED","sponsor":"Dr. Milan Gupta","startDate":"2006-04","conditions":"Type 2 Diabetes Mellitus","enrollment":103},{"nctId":"NCT00541775","phase":"PHASE3","title":"Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Type 2 Diabetes Mellitus","enrollment":273},{"nctId":"NCT01209143","phase":"PHASE1","title":"A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-11","conditions":"Solid Cancers","enrollment":52},{"nctId":"NCT00884533","phase":"PHASE1","title":"QTc Study of Rosi XR in Healthy Volunteers","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2009-06","conditions":"Alzheimer's Disease","enrollment":""},{"nctId":"NCT00295633","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-03","conditions":"Diabetes Mellitus, Type 2","enrollment":565},{"nctId":"NCT00819910","phase":"PHASE4","title":"Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)","status":"TERMINATED","sponsor":"Ahmad Slim","startDate":"2008-09","conditions":"Hypertriglyceridemia in Type 4 Hyperlipidemia, Non Diabetic Subjects With Normoglycemia","enrollment":41},{"nctId":"NCT00618072","phase":"PHASE2","title":"EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2008-01","conditions":"Hyperinsulinemia, Insulin Resistance, Obesity","enrollment":46},{"nctId":"NCT00130286","phase":"PHASE1, PHASE2","title":"Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2005-03","conditions":"HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections","enrollment":77},{"nctId":"NCT00680745","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":597},{"nctId":"NCT01100619","phase":"PHASE1","title":"A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors","status":"COMPLETED","sponsor":"Exelixis","startDate":"2010-04","conditions":"Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer","enrollment":40},{"nctId":"NCT00131664","phase":"PHASE3","title":"Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)","status":"COMPLETED","sponsor":"Canadian Heart Research Centre","startDate":"2005-09","conditions":"Type 2 Diabetes Mellitus","enrollment":391},{"nctId":"NCT00785213","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone","status":"COMPLETED","sponsor":"Mutual Pharmaceutical Company, Inc.","startDate":"2008-09","conditions":"Healthy","enrollment":23},{"nctId":"NCT01574820","phase":"PHASE3","title":"Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2006-11","conditions":"Prediabetes, Coronary Artery Disease, Insulin Resistance","enrollment":105},{"nctId":"NCT00331487","phase":"PHASE3","title":"Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2000-09","conditions":"Diabetes Mellitus","enrollment":719},{"nctId":"NCT00207402","phase":"PHASE4","title":"Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin","status":"COMPLETED","sponsor":"Brooke Army Medical Center","startDate":"2005-10","conditions":"Hepatitis C","enrollment":34},{"nctId":"NCT00324675","phase":"NA","title":"Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2006-08","conditions":"Type 2 Diabetes, Overt Diabetic Nephropathy","enrollment":28},{"nctId":"NCT00240604","phase":"PHASE3","title":"Prevention of Corticosteroid-induced Glucose Intolerance","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2005-04","conditions":"Glucose Intolerance","enrollment":100},{"nctId":"NCT00242593","phase":"PHASE2","title":"Rosiglitazone Effects on Cognition for Adults in Later Life","status":"UNKNOWN","sponsor":"University of Washington","startDate":"2006-06","conditions":"Mild Cognitive Impairment","enrollment":120},{"nctId":"NCT00362726","phase":"PHASE1","title":"Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-09","conditions":"HIV Infections","enrollment":14},{"nctId":"NCT01060566","phase":"PHASE1","title":"Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2010-02","conditions":"Cystic Fibrosis","enrollment":24},{"nctId":"NCT00675740","phase":"PHASE4","title":"Physical Exercise Versus Rosiglitazone in CAD and Prediabetes","status":"COMPLETED","sponsor":"University of Leipzig","startDate":"2004-01","conditions":"Impaired Glucose Tolerance","enrollment":45},{"nctId":"NCT00571506","phase":"PHASE4","title":"Effect of Thiazolidinedione Treatment Vascular Risk Markers","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2004-05","conditions":"Diabetes Mellitus, Type 2, Vascular Diseases","enrollment":25},{"nctId":"NCT00699036","phase":"PHASE2","title":"Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)","status":"UNKNOWN","sponsor":"Brooke Army Medical Center","startDate":"2007-04","conditions":"Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease","enrollment":165},{"nctId":"NCT00166803","phase":"NA","title":"The Impact of Rosiglitazone on Regression of Atherosclerosis","status":"SUSPENDED","sponsor":"National Taiwan University Hospital","startDate":"2005-06","conditions":"Diabetes Mellitus, Atherosclerosis","enrollment":60},{"nctId":"NCT00776607","phase":"NA","title":"Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA)","status":"UNKNOWN","sponsor":"Abertawe Bro Morgannwg University NHS Trust","startDate":"2007-04","conditions":"Latent Autoimmune Diabetes in Adults LADA","enrollment":200},{"nctId":"NCT00169832","phase":"PHASE3","title":"Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY Trial","status":"COMPLETED","sponsor":"Laval University","startDate":"2003-06","conditions":"Diabetes, Coronary Artery Bypass Grafting","enrollment":193},{"nctId":"NCT00361868","phase":"PHASE3","title":"Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI","status":"TERMINATED","sponsor":"Solvay Pharmaceuticals","startDate":"2006-06","conditions":"Dyslipidemia, Glucose Metabolism Disorder","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":51,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"rosiglitazone (4 mg)/day","genericName":"rosiglitazone (4 mg)/day","companyName":"National Cheng-Kung University Hospital","companyId":"national-cheng-kung-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosiglitazone activates PPAR-γ, leading to increased insulin sensitivity and glucose uptake in adipose tissue. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}